The rise of copyright’s blockbuster initially fueled a period of growth for major pharmaceutical companies, however recent changes present a murky picture for shareholders. Lower-cost competitors are eroding profits, https://idaaeno128569.jts-blog.com/39807750/the-blue-pill-and-big-pharma-a-precarious-play